Three-year efficacy and safety update from the phase III Checkmate 025 study of nivolumab (NIVO) v everolimus (EVE) in patients with advanced renal cell carcinoma (aRCC) Meeting Abstract
| Authors: | Sharma, P.; Tykodi, S. S.; Escudier, B.; Carducci, M.; Oudard, S.; Hammers, H. J.; George, S.; Gauna, D. C.; Alva, A. S.; Richardet, M. E.; Chevreau, C.; Plimack, E. R.; Srinivas, S.; Procopio, G.; Sosman, J. A.; McDermott, D.; Choueiri, T. K.; Gauler, T.; Berghorn, E.; Yang, L.; Motzer, R. |
| Abstract Title: | Three-year efficacy and safety update from the phase III Checkmate 025 study of nivolumab (NIVO) v everolimus (EVE) in patients with advanced renal cell carcinoma (aRCC) |
| Meeting Title: | 33rd Deutscher Krebskongress |
| Journal Title: | Oncology Research and Treatment |
| Volume: | 41 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2018 Feb 21-24 |
| Meeting Location: | Berlin, Germany |
| ISSN: | 2296-5270 |
| Publisher: | S. Karger AG |
| Date Published: | 2018-02-01 |
| Start Page: | 78 |
| Language: | English |
| ACCESSION: | WOS:000424914300208 |
| PROVIDER: | wos |
| PUBMED: | 29421791 |
| DOI: | 10.1159/000487109 |
| Notes: | "German Cancer Congress" -- Meeting Abstract: 764 -- Source: Wos |
